Maze Therapeutics Welcomes Hervé Hoppenot as Chairman
Maze Therapeutics, Inc. (Nasdaq: MAZE), a pioneering clinical-stage biopharmaceutical company focused on innovative small molecule precision medicines for patients with kidney and metabolic diseases, has announced a significant leadership change. Hervé Hoppenot has been appointed as the new Chairman of the Board of Directors, taking over from Charles Homcy, M.D., who will remain on the Board.
A Vision for Transformation
Hervé Hoppenot expressed his excitement about taking on this vital role at Maze Therapeutics, particularly at a time ripe with opportunities. With promising first-in-human data for MZE782, an oversubscribed $150 million private placement, and several key clinical milestones on the horizon, including the advancement of MZE829 targeting APOL1-mediated kidney disease, there is a palpable sense of optimism within the company. Hoppenot is poised to drive meaningful progress as the company continues to execute its mission in developing therapies that have the potential to change lives.
Experience and Leadership Skills
With over thirty years of robust experience in therapeutic development and commercial leadership, Hoppenot brings a wealth of knowledge to the Maze Board. His recent tenure as Chief Executive Officer at Incyte Corporation, which spanned from 2014 to 2025, has equipped him with invaluable insights. During his time at Incyte, he played a crucial role in transforming the organization from a single-product entity into a diversified biotech leader, growing revenues from $350 million to over $4 billion.
Recognizing Achievements
Jason Coloma, Ph.D., the chief executive officer of Maze, highlighted Hoppenot's extensive company-building experience, acknowledging the substantial contributions he made at Incyte. Hoppenot's leadership will be critical as Maze progresses towards its upcoming milestones in 2026, including initiating Phase 2 trials for MZE782 in both phenylketonuria (PKU) and chronic kidney disease (CKD), as well as the top-line Phase 2 data readout for MZE829 in APOL1-mediated kidney disease. Hoppenot's expertise is expected to propel the company toward delivering transformational therapies for patients.
Acknowledging Contributions
The transition comes with deep gratitude towards Charles Homcy, one of the company's co-founders. His tenure as Chairman has been pivotal in establishing the scientific foundation and the clinical trajectory of Maze Therapeutics. As Homcy steps back from the chairman role, the company is thrilled he will remain an active member of the Board and the R&D Committee, continuing to lend his expertise during this transition.
Maze Therapeutics' Commitment to Innovation
Maze Therapeutics is dedicated to leveraging the power of human genetics to create novel small molecule precision medicines. Guided by their renowned Compass™ platform, the company focuses on genetically validated targets, integrating variant discovery and functionalization, which enables them to advance small molecule programs exhibiting first- or best-in-class potential. Their leading programs include MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease, and MZE782, a SLC6A19 inhibitor progressing to Phase 2 trials.
Company Information and Resources
Based in South San Francisco, Maze Therapeutics continues to expand its horizons, aiming to address significant unmet medical needs. For more information, you can visit their official website or follow the company on social media platforms. Contact details for further inquiries include Amy Bachrodt for investor relations, and Amanda Lazaro for media relations, both of whom are readily available to provide insights into the company's latest developments.
Frequently Asked Questions
Who is the new Chairman of Maze Therapeutics?
The new Chairman of Maze Therapeutics is Hervé Hoppenot, who succeeds Charles Homcy.
What is Maze Therapeutics focusing on?
Maze Therapeutics specializes in developing small molecule precision medicines for kidney and metabolic diseases.
What are the significant projects under Maze Therapeutics?
The company is advancing MZE829 for APOL1-mediated kidney disease and MZE782 for PKU and CKD.
Where is Maze Therapeutics located?
Maze Therapeutics is headquartered in South San Francisco.
How can I contact Maze Therapeutics?
For inquiries, you can contact Amy Bachrodt for investor relations at abachrodt@mazetx.com or Amanda Lazaro for media inquiries at Amanda@1ABMedia.com.
